We have recently discovered a unique CD34 lo CD133 lo cell population in the human fetal liver (FL) that gives rise to cells in the hepatic lineage. In this study, we further characterized the biological functions of FL CD34 lo CD133 lo cells. Our findings show that these CD34 lo CD133 lo cells express markers of both endodermal and mesodermal lineages and have the capability to differentiate into hepatocyte and mesenchymal lineage cells by ex vivo differentiation assays. Furthermore, we show that CD34 lo CD133 lo cells express growth factors that are important for human hematopoietic stem cell (HSC) expansion: stem cell factor (SCF), insulin-like growth factor 2 (IGF2), C-X-C motif chemokine 12 (CXCL12), and factors in the angiopoietin-like protein family. Co-culture of autologous FL HSCs and allogenic HSCs derived from cord blood with CD34 lo CD133 lo cells supports and expands both types of HSCs.These findings are not only essential for extending our understanding of the HSC niche during the development of embryonic and fetal hematopoiesis but will also potentially benefit adult stem cell transplantations in clinics because expanded HSCs demonstrate the same capacity as primary cells to reconstitute the human immune system and mediate long-term hematopoiesis in vivo. Together, CD34 lo CD133 lo cells not only serve as stem/progenitor cells for liver development but are also an essential component of the HSC niche in the human FL. Cellular & Molecular Immunology
INTRODUCTION
Human adult hematopoietic stem cells (HSCs) are normally quiescent in the bone marrow (BM) and undergo limited selfrenewal. By contrast, within the human fetal liver (FL), there is a higher frequency of cycling HSCs undergoing self-renewal, which suggests that the FL provides a microenvironment that is more conducive in supporting HSCs. Thus, the FL is an ideal place to study hematopoiesis and characterize the specialized HSC niches created by the surrounding stromal cells. Although the exact cellular niches that support HSC self-renewal in the FL have not been defined, endothelial cells, stromal cells, and perhaps developing hepatocytes likely provide cues to the hematopoietic microenvironment. 1 In rodents, Zhang et al. showed that liver-derived cell lines express proteins such as IGF2 and angiopoietin-like factors that are associated with supporting HSCs. 2 Recently, it has been reported that hepatic progenitors in mouse FLs are stromal cells that support HSCs. 3 However, little is known about the human FL niche due to ethical constraints and limited access to human samples.
For decades, various human stem cells, such as hematopoietic, mesenchymal and other stem cells within fetal tissue transplants, have been utilized clinically to treat a spectrum of hematological malignancies, cancers, and genetic immune disorders. 4, 5, 6, 7, 8 Different stem cell sources, such as CB, peripheral blood, and BM are used for transplantation. 4, 5, 6, 7, 8 However, due to a scarcity of donors and a limited number of cells from these organs, stem cell use has been restricted to low body-weight recipients. 9 In recent years, a great deal of research has been focused on expanding and maintaining the number of HSCs in culture. These experiments range from supplementing the culture with undefined factors such as serum to the addition of feeder cells. 2, 10, 11, 12 However, there remains a need for more efficient protocols to expand HSCs while maintaining their potency and stemness. Increasing our depth of understanding of stem cell environments will not only increase the number of patients benefiting from allogenic transplantation but also reduce the overall mortality rate. 13 In a previous study, we discovered a novel human hepatic stem/progenitor cell population in the FL that has a phenotype of CD34 lo CD133 lo14 . Despite its ability to differentiate into human hepatocytes, little is known about this population. Therefore, further characterization of this CD34 lo CD133 lo cell population is required to explore more of its biological functions. Here, we report that CD34 lo CD133
lo cells are an important component of the FL niche because they are capable of developing into various endodermal and mesodermal cell types. In this sense, CD34 lo CD133 lo cells are not just restricted to the hepatic lineages. Furthermore, CD34 lo CD133 lo cells express principal growth factors that are important for HSC expansion and are capable of supporting the ex vivo expansion of HSCs.
MATERIALS AND METHODS

Mice
NOD-SCIDIL2Rc
2/2 (NSG) mice were obtained from the Jackson Laboratory and bred in the animal facility at A*STAR, Biological Resource Centre. Neonate mice were sublethally irradiated (100 rads) within 24 hours of birth and infused with cells via intra-hepatic injection. The International Animal Care and Use Committee (IACUC) at A*STAR specifically approved this study with the protocol number BRC #120716. All animal experimental procedures were performed in accordance with this protocol. 
FL processing and cell isolation
CD133
lo cells were trans-differentiated over 3 weeks in a two-step protocol.
Step 1 differentiation medium consisted of IMDM (Sigma), 100 ng/mL ActivinA (R&D), 10 ng/mL FGF2 (Peprotech), 200 mL insulin-transferrin-sodium selenite media supplement (ITS) (Sigma), 50 mMb-mercaptoethanol (Gibco), and 100 units penicillin/streptomycin (Gibco).
Step 2 medium contained 20 ng/mL hepatocyte growth factor (HGF) (R&D), 10 ng/mL FGF2 (Peprotech), 0.61 mg/mL Nicotinamide (Sigma), 50 ng/mL ITS (Sigma), 50 mMbmercaptoethanol (Gibco), and 100 units penicillin/streptomycin (Gibco). Medium changes were performed twice weekly, and hepatogenesis was assessed with a Fluoview inverted confocal (multi-photon) microscope (Olympus) to check for albumin (ALB) production. lo cells alone and a co-culture at a ratio of 1:7. Prior to this experiment, a range of co-culture conditions were tested, including 1:3, 1:5, 1:7, 1:10, and 1:20 (data not shown). The ratio of 1:7 was chosen as it was found to be the condition showing the highest viability, expansion, and stemness of HSCs. Cells were cultured for 7 days in serum-free StemSpan medium (Stem Cell Technologies) in the presence of defined factors: 20 ng/mL SCF (R&D), 10 ng/mL thrombopoietin (TPO) (R&D), 10 ng/mL fibroblast growth factor 1 (FGF1) (Gibco), 100 ng/mL insulin-like growth factor binding protein 2 (IGFBP2) (R&D), 10 ng/mL Heparin (Sigma), 50 mMb-mercaptoethanol (Gibco), and 100 units penicillin/streptomycin (Gibco). At different time points, cells were resuspended, counted, and stained on ice for 30 minutes with anti-human CD34 and CD133 antibodies and analyzed by flow cytometry. An experiment using the same conditions with the addition of transwells (Millipore) was designed to test if cellcell contact is essential for HSC expansion.
Immunostaining
Flow cytometry
Conjugated antibodies specific for human CD45 (HI30), CD34 (561), CD14 (M5E2), CD56 (HCD56), CD3 (HIT3a), CD19 (HIB19), CD303 (201A), ILT7 (17G10.2), and mouse CD45.1 (A20) were obtained from BioLegend; antibodies against CD133 (EMK08) were purchased from Miltenyi. Cells were stained with appropriate antibodies in 100 ml PBS containing 0.2% BSA and 0.05% sodium azide for 30 minutes on ice. Flow cytometry was performed on a LSRII flow cytometer with FACSDiva software (BD, Franklin Lakes, NJ); 5000 events were collected per sample, and the data were analyzed on FlowJo software 8.8.6 (Treestar, Ashland, OR, USA). Cell sorting was performed on an Aria cell sorter (Beckton Dickinson); the purity of sorted cells was between 90% and 99%.
Secondary transplantation and limiting dilution assay HSCs and CD34
lo CD133 lo cells were mixed at a ratio of 1:7 and cultured for 7 days. CD34 hi CD133 hi HSCs were re-purified from the co-culture by cell sorting. CD34 hi CD133 hi HSCs freshly isolated from the same FL donor were used as control. Cells were counted, and 400, 1000, 5000, or 100 000 HSCs were injected into each sublethally irradiated neonate NSG mouse. Eight weeks after injection, BM was harvested and to determine the amount of human cell reconstitution. Single-cell suspensions were prepared from the BM by flushing it with a 27 gauge needle and syringe. BM cells were stained with anti-mouse CD45.1, anti-human CD45, CD34, and CD133 and analyzed by flow cytometry. Chimerism was calculated by the following
RNA isolation and quantitative RT-PCR (qPCR)
RNA isolation was performed with RNeasy Mini and Micro kits (Qiagen). Reverse transcription was performed using the iScript cDNA Synthesis Kit (BIO-RAD) according to manufacturer's specifications. All values were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control. Data were analyzed with the comparative CT method in which gene expression is calculated as 2
2DDCT
, where Delta Ct 5 (Ct gene of interest -Ct GADPH internal control). The primer sequences used to detect endoderm, general endoderm, and mesoderm genes are listed in Supplementary Table 1 .
Statistical analysis
Data are represented by mean 6 standard error of the mean (SEM). lo cells were purified ( Figure 1A ) and analyzed for a panel of endodermal-and mesodermal-associated genes. The results showed that CD34 lo CD133 lo cells expressed the liver-associated endodermal markers ALB, alpha-fetoprotein (AFP), cytokeratin 19 (CK19) (Figure 1B ), other general endodermal markers such as laminin, GATA4, and SOX7 ( Figure 1C ) and mesodermal markers including CD73, VEcadherin, and vimentin ( Figure 1D ), whereas HSCs from the same donors did not express these genes.
RESULTS
CD34
In light of the expression of both endodermal and mesodermal markers by CD34 lo CD133 lo cells, we investigated whether these cells have the capacity to develop into liver and mesodermal cell lineages. We first purified CD34 lo cells endogenously expressed CD31, the expression of CD31 was further upregulated in the differentiated endothelial cells ( Figure 2C ). In adipocyte induction media, the cells increased in size, and 40% stained positive for fat (using Oil Red O) ( Figure 2D ). When cultured in osteocyte differentiation medium, the cells became elongated and 30% stained positive for calcium deposits (using Alizarin Red S) ( Figure 2E) . These data clearly demonstrate that CD34 lo CD133 lo cells contain progenitor cells that can give rise to hepatocyte-like and mesodermal-like cell lineages. Figure 3A) . Importantly, CXCL12, which is an HSC trafficking regulator secreted by stromal cells, 15 was also found to be highly expressed by CD34 lo CD133 lo cells ( Figure 3A) . Members of the angiopoietin-like protein (ANGPTL) family are known to play an important role in maintaining HSC homeostasis. 2 We were able to detect ANGPTLs (ANGPTL1 through ANGPTL6) mRNA enrichment in CD34 lo CD133
lo cells ( Figure 3A ). ANGPTL 2, 3, 5, and 6 were particularly highly expressed. Immunofluorescence stains confirmed the protein expression of SCF, DLK1, and CXCL12 in CD34 lo CD133
lo cells ( Figure 3B ).
To determine whether CD34 lo CD133 lo cells support the ex vivo expansion of HSCs, CD34
hi CD133 hi HSCs and CD34 lo CD133 lo cells were purified by cell sorting and seeded at a ratio of 1:7, respectively. Cultures of HSCs alone were used as a control. At the beginning of the co-culture, .95% of the initial HSCs were CD34 hi CD133 hi . After culture for 4 days, the percentage of CD34 hi CD133 hi cells decreased to ,25% in the co-cultures and ,45% in the control cultures ( Figure 4A ). The percentages continued to decrease, and by day 7 CD34
hi CD133 hi cells accounted for ,14% of cells in the cocultures and ,25% in the control cultures. When CD34 lo CD133 lo cells were cultured alone in the same HSC expansion medium, they attached to the bottom of wells and did not grow; hence, we counted the cells grown in suspension as expanded hematopoietic cells. Despite the decrease in the percentages of CD34 hi CD133 hi cells in the cultures because the total cell numbers increased dramatically (,140-fold in coculture versus ,16-fold in control on day 7) (Figure 4B ), the actual numbers of CD34 hi CD133 hi HSCs were increased ,18-fold in co-cultures, and ,3-fold in control cultures at day 7 ( Figure 4C ).
To investigate whether direct cell-cell contact is required for the HSC-CD34 lo CD133 lo co-culture cell expansion, the contact between HSCs and CD34 lo CD133 lo cells was blocked by a transwell. Compared to co-culture without the transwell, the percentage of CD34 hi CD133 hi cells (Figure 4D ), total and CD34 hi CD133 hi cell numbers ( Figure 4E and F) were not significantly different. This result suggests that the HSC expansion is supported by soluble growth factors rather than contactdependent signals produced by CD34 lo
CD133
lo cells. The use of CB transplants has increased for both children and adults to cure blood diseases. Given that the HSC expansion supported by CD34 lo CD133 lo cells is independent of autologous cell-cell contact, it is interesting to test whether our co-culture system could also support the expansion of allogeneic CB HSCs. Purified CD34 1 CD133 1 CB HSCs were cocultured with CD34 lo CD133 lo cells at a ratio of 1:7. Similar to FL HSCs, CB HSCs expanded well in co-culture with CD34 lo CD133 lo cells ( Figure 4G ). The results of this experiment demonstrated that the numbers of total cells ( Figure 4H ) and CD34
1 CD133 1 CB HSCs ( Figure 4I ) dramatically increased by 150-fold and 12-fold, respectively, in co-culture. These results show that the growth factors produced by CD34 lo CD133 lo cells also support the expansion of allogeneic HSCs.
Expanded HSCs maintain long-term repopulating activity in vivo
To investigate whether the HSCs expanded in our co-culture system maintained their stemness and long-term self-renewing capacities, we assessed the repopulating activity of expanded cells by in vivo secondary transplantation and serial limiting dilution in immunodeficient NSG mice. For secondary transplantation ( Figure 5A ), CD34 hi CD133 hi HSCs were purified from CD34 lo CD133 lo cells from the co-cultures and injected into sublethally irradiated neonates at 100 000 cells per mouse. Eight weeks post-transplantation, the human chimerism in the mouse peripheral blood and BM was analyzed by the staining of human CD45 and mouse CD45.1. Among total peripheral blood mononuclear cells (PBMCs), human CD45 1 leukocyte reconstitution levels ranged from 10% to 60% ( Figure 5B ). In BM, the chimera levels ranged from 15% to 45% ( Figure 5C ). Additionally, CD34
1 cells were purified from BM mononuclear cells (MNCs) and transplanted into sublethally irradiated secondary recipient neonates at 100 000 CD34 hi CD133 hi HSCs per mouse. Eight weeks post transplantation, PBMCs and BM MNCs were analyzed by staining human CD45 and mouse CD45.1. The human CD45 1 cell chimerism in primary and secondary recipient mice was similar ( Figure 5D ). All the major immune cell types, including human CD56
1 NK cells, CD14 1 monocytes/macrophages, CD3 1 T cells, CD19 1 B cells, and CD303
1 ILT7 1 plasmacytoid dendritic cells, were found in the secondary recipient mice ( Figure 5E ). Moreover, CD34 hi CD133
hi HSCs were still detectable, with a frequency of ,1% in the BM of secondary recipient mice ( Figure 5F ). These results indicate that despite ,15-fold expansion, HSCs from our co-culture system maintain their long-term repopulating capability.
For the serial limiting dilution assay, CD34 hi HSCs were diluted, and 400, 1000, or 5000 cells were injected into each sublethally irradiated neonate ( Figure 6A ). Even with these limited number of HSCs engrafted, considerable levels of human chimerism were achieved in the BM of recipient mice. Furthermore, both the expanded and fresh HSCs gave rise to similar levels of chimerism ( Figure 6B ). These results show that despite dramatic expansion, the cultured HSCs maintained the same self-renewing and repopulating capacities found in fresh HSCs. cells are different from the previously reported hepatic progenitor cells because they express liver-associated endodermal genes (ALB, AFP, and CK19), general endodermal genes (laminin, GATA4, and SOX7) and mesodermal genes (CD73, VE-Cadherin, and vimentin lo cells express endodermal markers. It has been hypothesized that the mesoderm and endoderm arise from a bipotential germ layer called the mesendoderm.
DISCUSSION
19 CD34 lo CD133 lo cells carry characteristics of both mesoderm and endoderm; however, whether they originated from mesendodermremains unknown.
From previous studies, it is known that the fate of HSCs is highly dependent on their in vivo niche. 20 There have been studies attempting to characterize HSC niches in major hematopoietic organs such as CB, adult BM, and fetal tissues by using stromal cells such as MSCs from these organs to mimic the in vivo environment in ex vivo co-culture systems to support HSCs expansion. 12, 21, 22, 23, 24, 25, 26 Depending on the co-culture conditions, 80-to 800-fold increases in total cell numbers and 4-to 100-fold increases in CD34 1 cells were reported. As shown in Figure 1A, 1 cells is approximately 3-15% (unpublished data). Thus, CD34 lo CD133 lo cells constitute approximately 0.6,3% of cells in the FL. It has been observed that HSCs exponentially increase in number within the liver during early embryonic development. 27 Given their relative abundance, we believe that CD34 lo CD133 lo cells are crucial in creating a microenvironment for the expansion of HSCs in the FL. In our previous study, we demonstrated that CD34 hi CD133 hi FL cells are long-term HSCs with high in vivo repopulating and ex vivo colony-forming capacities, whereas CD34 hi CD133 2 cells are hematopoietic progenitor cells that are more differentiated and do not repopulate NSG mice in vivo.
14 Therefore, in this study, we used CD34 and CD133 coexpression in cultured cells as markers for long-term HSC activity. We verified that CD34 lo CD133 lo cells have a high expression of growth factors important for HSC homeostasis and expansion, including SCF, DLK1, IGF2, CXCL12, and ANGPTLs. Furthermore, we showed that CD34 lo cells and use these to optimize a feeder-cellfree protocol for HSC expansion, which would greatly benefit the treatment of blood diseases. Given the high demand for stem cell therapy and a cure for cancer, this population of cells has a potential clinical significance, and discovering its underlying mechanisms can open doors for many unanswered questions. hi HSCs were purified from the day 7 co-culture and injected into sublethally irradiated NSG pups at 100 000 cells/mouse (primary recipient mice, n 5 5). Eight weeks later, PBMCs and BM MNCs were prepared from primary recipient mice and analyzed by flow cytometry. Subsequently, CD34
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1 cells were purified from the BM of primary recipient mice and injected into sublethally irradiated NSG pups at 100 000 CD34 hi CD133 hi HSCs/mouse (secondary recipient mice, n 5 5). Eight weeks later, PBMCs and BM MNCs were prepared from secondary recipient mice for flow analysis. 
